Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E10.59 EPS (ttm)24.45 Insider Own0.10% Shs Outstand153.40M Perf Week-4.23%
Market Cap39.47B Forward P/E12.88 EPS next Y20.11 Insider Trans1.67% Shs Float151.36M Perf Month-3.07%
Income4.00B PEG- EPS next Q5.02 Inst Own87.00% Short Float2.41% Perf Quarter-4.12%
Sales13.44B P/S2.94 EPS this Y-21.10% Inst Trans-2.09% Short Ratio2.95 Perf Half Y-3.64%
Book/sh69.75 P/B3.71 EPS next Y8.79% ROA15.80% Target Price290.28 Perf Year-21.28%
Cash/sh17.13 P/C15.12 EPS next 5Y-10.23% ROE35.30% 52W Range223.25 - 363.92 Perf YTD5.77%
Dividend- P/FCF9.50 EPS past 5Y10.10% ROI19.60% 52W High-28.83% Beta0.44
Dividend %- Quick Ratio1.60 Sales past 5Y4.50% Gross Margin86.60% 52W Low16.01% ATR7.10
Employees9100 Current Ratio1.80 Sales Q/Q-22.30% Oper. Margin33.80% RSI (14)39.01 Volatility2.29% 2.26%
OptionableYes Debt/Eq0.69 EPS Q/Q-71.30% Profit Margin29.80% Rel Volume1.96 Prev Close259.00
ShortableYes LT Debt/Eq0.69 EarningsApr 22 BMO Payout0.00% Avg Volume1.24M Price259.00
Recom2.70 SMA20-4.42% SMA50-4.45% SMA200-3.70% Volume0 Change0.00%
Feb-05-21Downgrade DZ Bank Buy → Hold $264
Jan-29-21Upgrade Stifel Hold → Buy $258 → $358
Nov-10-20Upgrade DZ Bank Hold → Buy $265
Nov-09-20Reiterated H.C. Wainwright Buy $318 → $289
Nov-09-20Downgrade Cowen Outperform → Market Perform $215
Nov-09-20Downgrade BofA Securities Neutral → Underperform $240
Nov-09-20Downgrade Atlantic Equities Neutral → Underweight $175
Nov-04-20Upgrade Wells Fargo Equal Weight → Overweight $390
Nov-04-20Upgrade Jefferies Hold → Buy $450
Nov-04-20Upgrade BofA Securities Underperform → Neutral
Oct-28-20Initiated UBS Neutral $268
Jul-27-20Upgrade Morgan Stanley Underweight → Overweight $263 → $357
Jun-22-20Reiterated RBC Capital Mkts Sector Perform $303 → $273
Jun-22-20Downgrade Barclays Overweight → Equal Weight $370 → $280
Jun-09-20Downgrade Bernstein Outperform → Mkt Perform $360 → $297
Apr-23-20Downgrade Raymond James Mkt Perform → Underperform
Apr-23-20Downgrade Citigroup Neutral → Sell $365 → $240
Mar-31-20Initiated Wolfe Research Peer Perform
Feb-27-20Initiated Barclays Overweight $389
Jan-27-20Upgrade Canaccord Genuity Hold → Buy $360
Apr-22-21 04:13PM  
02:30PM  
12:36PM  
10:50AM  
10:16AM  
09:18AM  
08:25AM  
08:14AM  
07:47AM  
07:26AM  
07:16AM  
06:15AM  
Apr-21-21 04:36PM  
Apr-20-21 02:28AM  
Apr-19-21 07:38PM  
10:03AM  
08:44AM  
07:30AM  
Apr-16-21 07:05AM  
05:55AM  
Apr-15-21 04:30PM  
12:31PM  
08:18AM  
Apr-14-21 04:06PM  
Apr-13-21 05:27PM  
Apr-12-21 04:40PM  
04:30PM  
11:45AM  
07:00AM  
Apr-09-21 04:30PM  
Apr-08-21 04:20PM  
01:31PM  
11:12AM  
07:00AM  
Apr-07-21 07:30AM  
Apr-06-21 06:00AM  
Apr-03-21 11:56PM  
Mar-25-21 04:45PM  
03:13PM  
08:30AM  
Mar-21-21 10:35AM  
06:11AM  
Mar-19-21 04:33PM  
Mar-18-21 09:39AM  
Mar-17-21 06:00AM  
Mar-15-21 04:52PM  
07:47AM  
Mar-10-21 09:29AM  
Mar-09-21 04:55PM  
04:17PM  
Mar-08-21 09:20AM  
Mar-07-21 01:53AM  
Mar-05-21 11:30AM  
09:10AM  
Mar-04-21 08:06AM  
07:47AM  
Mar-01-21 05:11PM  
Feb-26-21 01:16PM  
Feb-24-21 04:28PM  
07:30AM  
06:53AM  
Feb-23-21 06:30AM  
Feb-20-21 06:12AM  
Feb-16-21 04:16PM  
Feb-12-21 10:00AM  
09:23AM  
06:25AM  
Feb-11-21 04:23PM  
12:00PM  
09:13AM  
08:03AM  
08:00AM  
07:30AM  
Feb-10-21 01:02PM  
01:00PM  
11:57AM  
Feb-09-21 06:27AM  
Feb-08-21 08:22AM  
Feb-07-21 01:44PM  
01:27PM  
Feb-06-21 01:52PM  
Feb-05-21 01:15AM  
Feb-04-21 04:10PM  
11:11AM  
09:10AM  
09:02AM  
09:00AM  
04:34AM  
Feb-03-21 04:40PM  
01:01PM  
12:52PM  
11:30AM  
10:25AM  
10:04AM  
08:39AM  
08:35AM  
08:21AM  
07:19AM  
06:15AM  
Feb-02-21 10:12AM  
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sandrock AlfredEVP, Research & DevelopmentFeb 12Option Exercise0.004,454019,715Feb 17 05:01 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.0016,289060,194Feb 17 05:03 PM
Kramer RobinSVP, Chief Accounting OfficerFeb 12Option Exercise0.003330706Feb 17 04:59 PM
Guindo ChirfiEVP Glob. Prod Strat and CommFeb 12Option Exercise0.003,15606,946Feb 17 04:58 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.002,92309,288Feb 17 04:56 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.001,57304,765Feb 17 04:54 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 12Option Exercise0.004,355043,509Feb 17 04:52 PM
Mantas Jesus BDirectorFeb 09Buy267.00898239,7662,943Feb 10 04:31 PM
Kramer RobinVP, Chief Accounting OfficerDec 03Option Exercise0.00740395Dec 07 09:08 PM
Guindo ChirfiEVP Glob. Prod Strat and CommDec 01Option Exercise0.0048104,004Dec 03 05:41 PM
Vounatsos MichelChief Executive OfficerNov 30Buy241.313,100748,04734,810Dec 01 04:57 PM
Sandrock AlfredEVP, Research & DevelopmentNov 04Sale350.001,500525,00013,066Nov 06 09:39 PM
Gregory GingerEVP, Human ResourcesJul 31Option Exercise0.0021204,786Aug 04 04:12 PM